Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females aged ≥18 years.~* Diagnosis of chronic plaque psoriasis for ≥6 months before baseline.~* Candidates for phototherapy and/or systemic therapy.~* ≥10% body surface area (BSA) involvement at screening and baseline.~* static Physician's Global Assessment (sPGA) score ≥3, and Psoriasis Area and Severity Index (PASI) score ≥12 at screening and baseline.~Exclusion Criteria:~* Clinically significant flare of psoriasis during the 12 weeks before baseline.~* Systemic nonbiologic psoriasis therapy or phototherapy within 4 weeks. prior to baseline or topical psoriasis treatment or medicated shampoo within 2 weeks prior to baseline .~* Current or recent use of any biologic agent within the required washout periods.~* Clinical evidence or suspicion of active tuberculosis or previously had evidence of active tuberculosis and did not receive appropriate and documented treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixekizumab single dose (Type: EXPERIMENTAL): Participants received single dose of 80mg Ixekizumab by subcutaneous injection.
- Ixekizumab Multiple Regimen 1 (80mg Q2W) (Type: EXPERIMENTAL): Participants received multiple doses of Ixekizumab starting with 160mg initial dose followed by 80mg every two weeks (Q2W) by subcutaneous injection.
- Ixekizumab Multiple Regimen 2 (80mg Q4W) (Type: EXPERIMENTAL): Participants received multiple doses of 80mg Ixekizumab starting with 160mg initial dose followed by 80mg every four weeks (Q4W) by subcutaneous injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).